NASDAQ : PLRZ
Polyrizon Ltd. — Key statistics
Healthcare · Biotechnology · Israel
Last price 10.75 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 26.11M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 26.37M |
| Enterprise Value | 10.30M |
Dates
| Measure | Value |
|---|
| Earnings Date | Dec 29, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 2.43M |
| Shares Outstanding | 2.43M |
| Shares Change (YoY) | +1,106.77% |
| Shares Change (QoQ) | +61.54% |
| Owned by Insiders (%) | 3.51% |
| Owned by Institutions (%) | 0.91% |
| Float | 2.13M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.94 |
| P/TBV Ratio | 1.26 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 36.37 |
| Quick Ratio | 35.88 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -21.42% |
| Return on Assets (ROA) | -23.30% |
| Return on Invested Capital (ROIC) | -23.74% |
| Return on Capital Employed (ROCE) | -33.28% |
| Weighted Average Cost of Capital (WACC) | -2.08% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.15M |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -1.15 |
| 52-Week Price Change | +79.49% |
| 50-Day Moving Average | 10.54 |
| 200-Day Moving Average | 12.61 |
| Relative Strength Index (RSI) | 61.12 |
| Average Volume (20 Days) | 24,739 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 68,324 |
| Short Previous Month | 50,816 |
| Short % of Shares Out | 2.81% |
| Short % of Float | 3.20% |
| Short Ratio (days to cover) | 2.37 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -8.13M |
| Pretax Income | -4.58M |
| Net Income | -4.58M |
| EBITDA | -7.82M |
| EBIT | -8.13M |
| Earnings Per Share (EPS) | -$3.13 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 16.07M |
| Total Debt | n/a |
| Net Cash | 16.07M |
| Net Cash Per Share | $6.62 |
| Equity (Book Value) | 24.41M |
| Book Value Per Share | 11.49 |
| Working Capital | 15.85M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -4.66M |
| Capital Expenditures | -8,000 |
| Depreciation & Amortization | 306,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -4.67M |
| FCF Per Share | -$1.92 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1,106.77% |
| Shareholder Yield | -1,106.77% |
| Earnings Yield | -28.80% |
| FCF Yield | -16.78% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Nov 28, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:6 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |